Patient Characteristics
| MRI result | PET/MRI SUVmax | |||||||||
| Patient no. | Age (y) | Sex | P/R | Hormone level | Half dose | Full dose | 18F-FDG | 68Ga-DOTATATE | Adenoma size (mm) | Immunohistochemical staining result |
| 1 | 31 | F | P | ACTH↑, F↑ | − | + | 7.56 | 2.83 | 6 × 5 × 5 | ACTH+, GH+, LH+ |
| 2 | 16 | M | P | ACTH↑, F↑ | − | + | 4.8 | 2.8 | 5 × 5 × 5 | ACTH+, GH+ |
| 3 | 26 | F | P | ACTH↑, F↑ | − | − | 3.1 | 2.09 | 8 × 3 × 3 | ACTH+, GH+ |
| 4 | 63 | F | P | GH↑, IGF1↑ | − | − | 10.21 | 5.23 | 7 × 5 × 5 | ACTH+, GH+, LH+, PRL+ |
| 5 | 38 | F | P | ACTH↑, F↑ | − | − | 4.81 | 1.24 | 5 × 4 × 3 | ACTH+ |
| 6 | 38 | F | P | ACTH↑, F↑ | − | − | 9.07 | 4.61 | 5 × 4 × 3 | ACTH+ |
| 7 | 16 | M | P | ACTH↑, F↑ | ± | + | 6.81 | 5.3 | 6 × 5 × 5 | ACTH+, GH+, LH+ |
| 8 | 28 | F | P | ACTH↑, F↑ | ± | + | 2.95 | 12.05 | 3 × 3 × 2 | ACTH+, GH+, LH+ |
| 9 | 63 | M | P | ACTH↑, F↑ | ± | − | 7.23 | 2.55 | 5 × 5 × 5 | ACTH+, GH+, LH+ |
| 10 | 26 | M | P | ACTH↑, F↑ | ± | − | 3.68 | 6.15 | 3 × 2 × 2 | ACTH+, GH+, LH+ |
| 11 | 17 | M | P | ACTH↑, F↑ | ± | − | 17.48 | 3.35 | 10 × 8 × 8 | ACTH+, GH+ |
| 12 | 50 | F | P | ACTH↑, F↑ | ± | + | 3.1 | 2.09 | 5 × 5 × 5 | ACTH+, GH+, LH+ |
| 13 | 38 | M | P | ACTH↑, F↑ | − | − | 9.69 | 2.28 | 5 × 3 × 3 | ACTH+, GH+ |
| 14 | 45 | F | P | ACTH↑, F↑ | − | + | 5.61 | 3.02 | 5 × 5 × 3 | ACTH+, GH+, LH+ |
| 15 | 20 | F | P | ACTH↑, F↑ | ± | − | 8.56 | 2.2 | 5 × 5 × 5 | ACTH+, GH+, LH+ |
| 16 | 16 | M | P | ACTH↑, F↑ | ± | − | 4.27 | 3.02 | 4 × 3 × 3 | ACTH+, GH+ |
| 17 | 20 | F | R | ACTH↑, F↑ | − | + | 5.58 | 5.38 | 5 × 5 × 5 | ACTH+, GH+ |
| 18 | 30 | F | R | ACTH↑, F↑ | − | + | 8.84 | 2.62 | 6 × 5 × 5 | ACTH+, GH+ |
| 19 | 25 | F | R | ACTH↑, F↑ | ± | + | 6.6 | 4.36 | 6 × 5 × 5 | ACTH+ |
| 20 | 31 | F | R | ACTH↑, F↑ | ± | + | 2.69 | 1.94 | 5 × 3 × 3 | ACTH−, FSH+, GH+, LH+ |
| 21 | 29 | F | R | ACTH↑, F↑ | ± | + | 5.4 | 3.83 | 5 × 5 × 5 | ACTH+, GH+, LH+ |
| 22 | 10 | F | R | ACTH↑, F↑ | − | − | 2.49 | 2.39 | 3 × 3 × 3 | ACTH+, GH+, LH+ |
| 23 | 45 | F | R | ACTH↑, F↑ | ± | + | 3.96 | 2.08 | 5 × 5 × 5 | ACTH+, GH+ |
| 24 | 35 | F | R | ACTH↑, F↑ | − | − | 13.3 | 2.35 | 5 × 5 × 5 | ACTH+, GH+ |
| 25 | 50 | F | R | ACTH↑, F↑ | − | − | 3.7 | 3.35 | 4 × 3 × 3 | ACTH+ |
| 26 | 41 | F | R | ACTH↑, F↑ | ± | + | 10.49 | 2.02 | 5 × 6 × 6 | ACTH+, GH+ |
| 27 | 32 | M | R | ACTH↑, F↑ | − | + | 3.52 | 2.81 | 5 × 5 × 4 | ACTH+, GH+, LH+ |
| 28 | 11 | F | P | ACTH↑, F↑ | − | − | 7.45 | 3.92 | NA | NA |
| 29 | 51 | M | P | ACTH↑, F↑ | − | + | 6.33 | 2.17 | NA | NA |
| 30 | 59 | F | P | ACTH↑, F↑ | ± | − | 4.23 | 2.15 | NA | NA |
| 31 | 55 | F | R | GH↑, IGF1↑ | − | − | 5.24 | 3.31 | NA | NA |
| 32 | 57 | M | R | T4↑ | − | + | 7.34 | 2.35 | NA | NA |
| 33 | 30 | F | R | GH↑, IGF1↑ | − | − | 9.56 | 3.22 | NA | NA |
| 34 | 34 | F | R | ACTH↑, F↑ | − | − | 8.28 | 2.13 | NA | NA |
| 35 | 17 | M | R | ACTH↑, F↑ | − | − | 5.21 | 3.28 | NA | NA |
| 36 | 39 | F | R | ACTH↑, F↑ | ± | − | 8.35 | 5.28 | NA | NA |
| 37 | 35 | F | R | ACTH↑, F↑ | ± | − | 4.38 | 3.17 | NA | NA |
P = primary; R = recurrent; half dose = 0.05 mmol/kg dose of gadopentetate dimeglumine; full dose = 0.1 mmol/kg dose of gadopentetate dimeglumine; ACTH = adrenocorticotropic hormone; F = cortisol (compound F); GH = growth hormone; LH = luteinizing hormone; IGF1 = insulinlike growth factor 1; PRL = prolactin; FSH = follicle-stimulating hormone; NA = not available because patient accepted clinical follow-up or treatments other than surgery; T4 = thyroxine; + = positive; − = negative.